Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

HIV Infection Clinical Trial

Official title:

Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00921557
• Other study ID #: P1076
• Secondary ID: 10669IMPAACT P10
• Status: Completed
• Phase: Phase 2
• Start date: November 2009
• Est. completion date: January 2017

Study information

• Verified date: June 2017
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be expected for HIV-uninfected people of similar age, weight and race. As the majority of perinatally HIV-infected U.S. children are entering or in adolescence, the potential for HIV-related impaired BMD during the adolescent peak of bone mass acquisition is of particular concern. The primary purpose of this study was to compare changes from pre-treatment levels of BMD of the lumbar spine after 24 and 48 weeks of alendronate treatment with placebo in HIV-infected children and adolescents.

Description:

Puberty is a time when the foundation is laid for healthy bone mass. Over the course of puberty, 26% of bone mass is established in the 4-year period of peak height velocity and up to 60% of adult peak bone mass is established. Factors that affect normal bone mineralization include calcium intake, vitamin D status, degree of physical and weight bearing activities, hormones, genetics, body weight, and general health and nutrition status. HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be expected for healthy people of similar age, weight, and race. As the majority of perinatally HIV-infected U.S. children are entering or in adolescence, the potential for HIV-related impaired BMD during the adolescent peak of bone mass acquisition is of particular concern. The purpose of this study was to compare changes in BMD of the lumbar spine from pre-treatment levels to 24 and 48 weeks after alendronate treatment or placebo in HIV-infected children and adolescents.

Participants were randomized equally into one of three groups: Group 1A received alendronate for 96 weeks; Group 1B received alendronate for 48 weeks followed by placebo for 48 weeks; Group 2 received placebo for 48 weeks followed by alendronate for 48 weeks. All three groups were followed off treatment for an additional 48 weeks. Participants also received vitamin D/calcium for the duration of the study and were asked to perform 60 minutes of weight-bearing exercise each day.

Clinic visits were scheduled every 12 weeks after entry, with telephone contact visits one, four, and 28 weeks after entry and the week 48 visit. A physical exam and dental assessment was conducted at each clinic visit, and a history of adverse events collected. Dual Energy X-ray absorptiometry (DXA), hematology and chemistry panels were conducted at entry and weeks 24, 48, 72, 96 and 144. Lumbar spine and whole body (with head) BMD was measured using Hologic DXA scanners (QDR4500A, QDR4500W or Delphi A models).

The primary analysis compared changes from entry to 24 and 48 weeks in lumbar spine BMD between Groups 1A and 1B combined (both on alendronate for initial 48 weeks) vs. Group 2 (on placebo for 48 weeks). Study participants were unblinded after 96 weeks of follow-up (the primary completion date) but remained on study, off study treatment, for an additional 48 weeks.

Secondary laboratory outcomes listed in the protocol (bone marker turnover and Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin (RANKL/OPG) Ratio) and central fat content, which required application for additional funding for laboratory testing, will not be performed and no results will be available.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: January 2017
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 11 Years to 24 Years

Eligibility

Inclusion Criteria (Version 2.0 of protocol):

• Documentation of HIV-1 infection

• HIV-infection acquired before puberty

• For participants receiving antiretroviral therapy, must have been on the same antiretroviral agents for at least 12 weeks prior to study entry and have a viral load less than 10,000 copies/mL. For participants not receiving antiretroviral therapy, must have not been on antiretroviral agents for at least 12 weeks prior to study entry and have no indication for therapy

• Lumbar spine DXA BMD z-score less than -1.5 or history of fragility fracture within the prior 12 months (regardless of DXA result).

• Available for routine dental exam and care every 6 months

• Demonstrated ability and willingness to swallow study medications

• Females of reproductive potential must have had a negative pregnancy test at screening and within 48 hours prior to study entry. They must also have agreed to avoid pregnancy while on the study and if engaging in sexual activity, use at least two forms of contraception.

• Parent or legal guardian able and willing to provide signed informed consent for children who could not provide consent for themselves.

Exclusion Criteria (Version 2.0 of protocol):

• Body weight more than 300 lbs.

• For female participants: if on Depo-Provera, they must have been on it for at least 1 year prior to study entry; if not on Depa-Provera, they must have not been on it for at least 1 year prior to study entry.

• Anticonvulsant therapy

• Proven growth hormone deficiency

• Use of growth hormone in the 12 months prior to entry

• Primary hyperparathyroidism

• Hypoparathyroidism

• Renal failure

• Cushing syndrome

• Active dental infection

• Dental or periodontal disease expected to require more than basic restorative care

• Pregnancy or lactation

• Esophageal or gastric ulcer, chronic nonsteroidal anti-inflammatory drug (NSAID) use, or aspirin use

• Tenofovir disoproxil fumarate (TDF): if on TDF, they must have been on it for at least 6 months prior to study entry; if not on TDF, they must have not been on it for at least 6 months prior to study entry.

• Hemoglobin less than 10 g/dL

• Any past pharmacologic treatment (except vitamin D and/or calcium supplementation) for low bone density

• Inability to stand or sit upright for at least 30 minutes

• Hypersensitivity to any component of alendronate

• Hypocalcemia (less than the lower limit of normal established by the local laboratory in which it was performed)

• Known abnormalities of the esophagus that delay esophageal emptying such as stricture or achalasia

• 25-OH vitamin D less than 10 ng/mL in combination with elevated intact PTH above the upper limit of normal for the local laboratory in which it was performed

Related Conditions & MeSH terms

• HIV Infection
• HIV Infections

Intervention

Drug:
• Alendronate
Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
• Placebo
Oral tablet taken once weekly

Dietary Supplement:
• Calcium carbonate/vitamin D
Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL

Locations

Country	Name	City	State
Brazil	SOM Federal University Minas Gerais Brazil NICHD CRS	Belo Horizonte	Minas Gerais
Brazil	Univ. of Sao Paulo Brazil NICHD CRS	Sao Paulo
Puerto Rico	San Juan City Hosp. PR NICHD CRS	San Juan
United States	Johns Hopkins Univ. Baltimore NICHD CRS	Baltimore	Maryland
United States	Lurie Children's Hospital of Chicago (LCH) CRS	Chicago	Illinois
United States	David Geffen School of Medicine at UCLA NICHD CRS	Los Angeles	California
United States	St. Jude Children's Research Hospital CRS	Memphis	Tennessee
United States	Pediatric Perinatal HIV Clinical Trials Unit CRS	Miami	Florida
United States	USF - Tampa NICHD CRS	Tampa	Florida
United States	WNE Maternal Pediatric Adolescent AIDS CRS	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Countries where clinical trial is conducted

United States,  Brazil,  Puerto Rico, 

References & Publications (4)

Clay PG, Voss LE, Williams C, Daume EC. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother. 2008 May;42(5):670-9. doi: 10.1345/aph.1K465. Epub 2008 Apr 15. Review. — View Citation

McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007 Nov 30;21(18):2473-82. — View Citation

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1. — View Citation

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009).

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD	Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B combined as both were on alendronate for the first 48 weeks.	Weeks 0, 24 and 48
Primary	Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures	Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks.	Week 0 to 48
Secondary	Percent Change From Baseline to Weeks 24 and 48 in Whole Body (With Head) BMD	Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks.	Weeks 0, 24 and 48
Secondary	Percent Change From Baseline to Week 96 in Lumbar Spine BMD	Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only.	Weeks 0 and 96
Secondary	Percent Change From Baseline to Week 96 in Whole Body (With Head) BMD	Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only.	Weeks 0 and 96
Secondary	Safety as Measured by the Incidence of New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures	Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004).	Weeks 0 to 144
Secondary	Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Lumbar Spine BMD	A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in lumbar spine BMD from baseline. Results represent average changes in lumbar spine BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks.	Weeks 0, 24 and 48
Secondary	Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Whole Body (With Head) BMD.	A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in whole body (with head) BMD from baseline. Results represent average changes in whole body (with head) BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks.	Weeks 0, 24 and 48
Secondary	Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Lumbar Spine BMD	Percent change was calculated as (measurement at time T2 - measurement at time T1)/measurement at Time T1 * 100%.	Weeks 48, 96 and 144
Secondary	Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Whole Body (With Head) BMD	Percent change was calculated as (measurement at time T2 - measurement at time T2)/measurement at time T1 * 100%.	Weeks 48, 96 and 144
Secondary	Change From Baseline to Week 48 in Bone Marker Turnover	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Correlation of Changes in Bone Marker Turnover With Changes in Lumbar Spine and Whole Body (With Head) BMD	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Change From Baseline to Week 48 in Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin (RANKL/OPG) Ratio	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Correlation of Changes in RANKL/OPG Ratio With Changes in Lumbar Spine and Whole Body (With Head) BMD	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Change From Baseline to Week 48 in Central Fat Content	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Correlation of Changes in Central Fat Content With Changes in Lumbar Spine and Whole Body (With Head) BMD	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 0 and 48
Secondary	Percent of Participants With HIV-1 RNA <= 400 Copies/ml	Percent calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point.	Weeks 0, 48, 96 and 144
Secondary	Change in CD4 Percent From Baseline	Change in percentage of lymphocytes that are CD4 cells calculated as measurement at each time point minus baseline measurement	Weeks 0, 48, 96 and 144
Secondary	Change in Centers for Disease Control (CDC) HIV Disease Category	Percentage of participants advancing in CDC HIV disease category from baseline throughout study follow-up	Weeks 144
Secondary	Percent of Participants With Detectable Urinary Alendronate	Outcome measure required additional funding for laboratory testing which was not available, so this outcome is not reported.	Weeks 48, 96 and 144